Suven Pharmaceuticals has officially rebranded as Cohance Lifesciences, marking a significant evolution in its strategic direction. The change, effective from May 7, 2025, follows the approval from India's Ministry of Corporate Affairs and is part of a broader Scheme of Amalgamation.

This rebranding signifies more than a name change; it reflects the company's transformation into a specialized, technology-driven global Contract Development and Manufacturing Organization (CDMO). Cohance Lifesciences aims to collaborate closely with global innovators to enhance their molecules and products, delivering transformative solutions to patients and consumers worldwide. The company is committed to enabling innovation across a broad range of modalities, chemistries, and technologies to advance solutions for a healthier world.

The company is in the process of updating its name in official documents and stock exchange records. Applications have been made to BSE Limited and the National Stock Exchange of India Limited to reflect the new name in their records. Additionally, the Name Clause in the company's Memorandum of Association has been updated to replace all mentions of "Suven Pharmaceuticals Limited" with "Cohance Lifesciences Limited" .

This strategic rebranding positions Cohance Lifesciences to better serve its customers and their end markets, building a global CDMO that supports innovation across various modalities, chemistries, and technologies. The company continues to focus on scaling high-growth areas such as Antibody-Drug Conjugates (ADCs) and oligonucleotides, aiming to deliver on its revenue ambitions through a mix of organic growth and strategic acquisitions.